Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Extracorporeal lung assist might avoid invasive ventilation in exacerbation of COPD

Jörg Brederlau, Thomas Wurmb, Stefan Wilczek, Kirstin Will, Sebastian Maier, Markus Kredel, Norbert Roewer, Ralf M Muellenbach
European Respiratory Journal 2012 40: 783-785; DOI: 10.1183/09031936.00006012
Jörg Brederlau
*Dept of Intensive Care Medicine, HELIOS Klinikum Berlin-Buch, Berlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: joerg.brederlau@helios-kliniken.de
Thomas Wurmb
#Dept of Anaesthesia and Critical Care, University of Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stefan Wilczek
*Dept of Intensive Care Medicine, HELIOS Klinikum Berlin-Buch, Berlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kirstin Will
*Dept of Intensive Care Medicine, HELIOS Klinikum Berlin-Buch, Berlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sebastian Maier
¶Dept of Internal Medicine, University of Würzburg, Würzburg, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Kredel
#Dept of Anaesthesia and Critical Care, University of Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Norbert Roewer
#Dept of Anaesthesia and Critical Care, University of Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ralf M Muellenbach
#Dept of Anaesthesia and Critical Care, University of Würzburg
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

To the Editors:

Acute exacerbation of chronic obstructive pulmonary disease (COPD) requiring invasive mechanical ventilation (IMV) is associated with a very poor prognosis. Therefore noninvasive mechanical ventilation (NIV) with avoidance of endotracheal intubation should be preferred. However, NIV can fail and result in severe respiratory acidosis. If IMV becomes mandatory, the development of pulmonary dynamic hyperinflation with subsequent barotrauma and circulatory failure is the main pathophysiological alteration.

Extracorporeal CO2 elimination, such as that provided by an arteriovenous extracorporeal lung assist system (avECLA), combined with NIV might be a therapeutic option in order to avoid IMV in patients with acute exacerbation of COPD (AECOPD). We present three cases with hypercapnic respiratory failure that were treated with NIV and extracorporeal lung assist for 2, 7 and 8 days, respectively. The combination of these two therapeutic approaches might be effective to prevent the potentially lethal side-effects of IMV in this group of multi-morbid patients.

COPD affects 4–7% of the general population and is the fourth leading cause of death in developed countries [1]. If patients with AECOPD require mechanical ventilation (MV), the mortality rate is 17–30% [2].

MV is mandatory in patients with AECOPD if decompensated hypercapnic respiratory failure is evident. NIV via face mask or helmet has been the evidence-based treatment of choice in AECOPD patients with hypercapnia for more than 20 yrs [3]. NIV has been shown to improve gas exchange and outcome when compared with IMV. However, in some cases NIV fails to eliminate CO2 sufficiently and tracheal intubation and IMV are traditionally regarded as the last treatment option [4]. The prognosis of the affected patients still remains very poor and, therefore, measures that result in avoidance of IMV might be rational [5].

Over 10 yrs ago, a pumpless avECLA consisting of an extracorporeal membrane lung with a minimal resistance to blood flow, that was shown to remove CO2 highly effectively in patients with acute respiratory distress syndrome, was introduced into clinical practice. AvECLA enables minute ventilation and peak inspiratory pressures to be reduced significantly following the rules of lung protective ventilation [6]. This was also shown for patients with asthma treated with IMV [7].

Thus, in AECOPD patients with decompensated respiratory acidosis that is refractory to NIV, the addition of avECLA might be able to avoid tracheal intubation and subsequent IMV. We report three AECOPD patients with decompensated respiratory acidosis treated with avECLA plus NIV.

The institutional review board approval to publish this patient data was obtained from the ethics committee of the University of Würzburg (Würzburg, Germany).

After ultrasonographic examination of the targeted vessels and exclusion of severe peripheral artery disease (PAD), avECLA was implanted using a 13-F cannula for the femoral artery and a 15- or 17-F cannula for the femoral vein, respectively. Anticoagulation was performed with a continuous heparin infusion resulting in a partial thromboplastin time of 40–60 s. With membrane lung blood flows ranging from 1.2 to 1.5 L·min−1 and oxygen sweep gas flows through the membrane lung of 1–10 L·min−1, the arterial carbon dioxide tension (Pa,CO2) was adjusted to values between 50 and 65 mmHg resulting in a pH of >7.2 (table 1). NIV was continued during avECLA treatment and positive end-expiratory pressure and pressure support were titrated to avoid tachypnoea and maintain oxygenation at an arterial oxygen tension (Pa,O2) between 50 and 60 mmHg.

View this table:
  • View inline
  • View popup
Table 1– Patient gas exchange, ventilator settings, haemodynamics and extracorporeal lung parameters

An 85-yr-old morbidly obese male patient was admitted to the emergency room and subsequently to the intensive care unit (ICU) with shortness of breath. His past medical history (PMH) consisted of congestive heart failure and COPD with ambulant oxygen treatment for 8 h·day−1. The chest radiograph and thoracic computed tomography (CT) scan showed cardiomegaly, basal pneumonic infiltrates and a known left indurative pleurisy. Assuming AECOPD, a calculated antibiotic therapy was initiated and piperacillin/tazobactam and prednisolone were administered. The patient developed decompensated respiratory acidosis. NIV via face mask did not result in amelioration of hypercapnia. 4 h after admission to the ICU avECLA was implanted. NIV via helmet combined with avECLA was performed for 8 days. Respiratory mechanics improved and signs of infection resolved. On day eight avECLA was removed uneventfully, NIV was continued for four more days without further decompensation of the respiratory acidosis. The patient was adapted to a home continuous positive airway pressure system and discharged home 4 days later.

A 66-yr-old male patient was admitted to the hospital with incremental deterioration of a chronic pulmonary infection. His main complaints were shortness of breath and continuously increasing adynamia. His PMH consisted of congestive heart failure, ventricular tachycardia with subsequent implantation of an automated cardioverter and COPD. The chest radiograph and the thoracic CT scan showed cardiomegaly, bilateral pneumonic infiltrates and right-sided bonchiectasis. Assuming AECOPD, a calculated antibiotic therapy was initiated and piperacillin/tazobactam and prednisolone were administered. The patient developed decompensated respiratory acidosis despite NIV via face mask. 12 h after admission to the ICU avECLA was implanted. NIV via face mask combined with avECLA was performed for 7 days. However, respiratory mechanics did not improve and after an initial phase of amelioration, oxygenation and haemodynamics deteriorated further (Pa,O2 40 mmHg, respiratory rate 35 breaths·min−1 and need for vasopressors) and signs of infection increased due to recurrence of pneumonia. Antibiotic therapy was switched to ceftazidim/ciprofloxacin. The patient’s trachea was intubated and IMV in a lung protective mode was performed. AvECLA was discontinued uneventfully. Tracheostomy was performed on the same day. On day 17 the patient was transferred to a weaning clinic and subsequently to a nursing home providing long-term respiratory care with IMV.

A 52-yr-old cachectic female patient was admitted to the ICU in severe respiratory distress. Auscultation of the chest revealed wheezing and a prolonged expiration. Her PMH was remarkable for arterial hypertension, COPD and pneumococcus pneumonia infection requiring IMV that was accompanied by acute renal failure 1 yr ago. NIV via face mask and anti-asthmatic medication were started immediately but did not ameliorate the severe respiratory acidosis with a Pa,CO2 of 140 mmHg. The chest radiograph showed bilateral infiltrates and the typical radiological signs of COPD. Calculated antibiotic therapy was initiated and ceftriaxone and clarithromycin and a bolus of prednisolone were administered. After avECLA was started a pH >7.2 was quickly achieved. Bronchospasm subsided and avECLA was discontinued 2 days later uneventfully. Nevertheless, due to insufficiency of the respiratory pump the patient was adapted to an ambulatory NIV system and subsequently discharged home.

The longer IMV is performed, the higher the risk of death [8]. Thus, avoidance of IMV is a rational therapeutic goal. In all three patients the combination of avECLA and NIV unloaded the respiratory pump and brought the pulmonary gas exchange to acceptable values (table 1]). In two cases IMV was avoided, in one case the concept failed due to recurrence of pneumonia and subsequent weaning failure.

A prerequisite to put the presented treatment approach into practice is the concept of dissociating the pulmonary gas exchange into its two components: CO2 elimination is provided with an extracorporeal lung and oxygenation is secured by an adequate level of mean airway pressure [9]. Whenever hypoxaemia occurs, the presented concept becomes obsolete, since O2 transfer via avECLA does not suffice [6].

Looking at the risk–benefit ratio, complications and costs related to avECLA need to be addressed. It is well known that arterial cannulation with large bore cannulas can cause limb ischaemia especially in multi-morbid patients with a high risk of PAD [6] Without negatively influencing the CO2 elimination rate, this risk can be reduced if cannulas with a diameter of >15-F are avoided. In addition, looking at the rapid progress in cannula and pump technology development, venovenous extracorporeal CO2 removal with double lumen cannulas requiring only one vascular access port might also be combined with NIV in patients with AECOPD even when PAD is evident [10]. Obviously costs for extracorporeal systems must be considered as well as ventilator free days and length of ICU stay.

In conclusion, the combination of NIV and extracorporeal CO2 elimination might be effective to prevent IMV and its potentially lethal side-effects in patients with AECOPD.

Footnotes

  • Statement of Interest

    A statement of interest for R.M. Muellenbach can be found at www.erj.ersjournals.com/site/misc/statements.xhtml

  • ©ERS 2012

REFERENCES

  1. ↵
    1. Ambrosino N,
    2. Simonds A
    . The clinical management in extremely severe COPD. Respir Med 2007; 101: 1613–1624.
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    1. Berry CE,
    2. Wise RA
    . Mortality in COPD: causes, risk factors, and prevention. COPD 2010; 7: 375–382.
    OpenUrl
  3. ↵
    1. Brochard L,
    2. Isabey D,
    3. Piquet J,
    4. et al
    . Reversal of acute exacerbations of chronic obstructive lung disease by inspiratory assistance with a face mask. N Engl J Med 1990; 323: 1523–1530.
    OpenUrlPubMedWeb of Science
  4. ↵
    1. Quinnell TG,
    2. Pilsworth S,
    3. Shneerson JM,
    4. et al
    . Prolonged invasive ventilation following acute ventilatory failure in COPD: weaning results, survival, and the role of noninvasive ventilation. Chest 2006; 129: 133–139.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Barnes PJ
    . New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010; 19: 330–338.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Muellenbach RM,
    2. Kredel M,
    3. Wunder C,
    4. et al
    . Arteriovenous extracorporeal lung assist as integral part of a multimodal treatment concept: a retrospective analysis of 22 patients with ARDS refractory to standard care. Eur J Anaesthesiol 2008; 25: 897–904.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Elliot SC,
    2. Paramasivam K,
    3. Oram J,
    4. et al
    . Pumpless extracorporeal carbon dioxide removal for life-threatening asthma. Crit Care Med 2007; 35: 945–948.
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    1. Esteban A,
    2. Anzueto A,
    3. Frutos F,
    4. et al
    . Characteristics and outcomes in adult patients receiving mechanical ventilation: a 28-day international study. JAMA 2002; 287: 345–355.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    1. Gattinoni L,
    2. Kolobow T,
    3. Tomlinson T,
    4. et al
    . Control of intermittent positive pressure breathing (IPPB) by extracorporeal removal of carbon dioxide. Br J Anaesth 1978; 50: 753–758.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Terragni P,
    2. Maiolo G,
    3. Ranieri VM
    . Role and potentials of low-flow CO2 removal system in mechanical ventilation. Curr Opin Crit Care 2012; 18: 93–98.
    OpenUrlCrossRefPubMed
View Abstract
PreviousNext
Back to top
View this article with LENS
Vol 40 Issue 3 Table of Contents
European Respiratory Journal: 40 (3)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Extracorporeal lung assist might avoid invasive ventilation in exacerbation of COPD
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Extracorporeal lung assist might avoid invasive ventilation in exacerbation of COPD
Jörg Brederlau, Thomas Wurmb, Stefan Wilczek, Kirstin Will, Sebastian Maier, Markus Kredel, Norbert Roewer, Ralf M Muellenbach
European Respiratory Journal Sep 2012, 40 (3) 783-785; DOI: 10.1183/09031936.00006012

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Extracorporeal lung assist might avoid invasive ventilation in exacerbation of COPD
Jörg Brederlau, Thomas Wurmb, Stefan Wilczek, Kirstin Will, Sebastian Maier, Markus Kredel, Norbert Roewer, Ralf M Muellenbach
European Respiratory Journal Sep 2012, 40 (3) 783-785; DOI: 10.1183/09031936.00006012
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • COPD and smoking
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • How can we achieve better prevention of TB among contacts?
  • Predictors of treatment outcome in MDR-TB in Portugal
  • Drug concentration in lung tissue in MDR-TB
Show more Letters

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society